

Claims:

1. Use of a P2Y₁₂ receptor antagonist, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the prevention or treatment of a disease, wherein the disease is selected from acute arterial thromboses and acute venous thromboses;

5 wherein the P2Y₁₂ receptor antagonist is 4-((*R*)-2-[[6-((*S*)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino]-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester; and wherein the P2Y₁₂ receptor antagonist is to be administered to a patient by subcutaneous administration.
2. The use according to claim 1, wherein the disease is selected from acute coronary syndromes, myocardial infarction, peripheral ischaemia, amaurosis, sudden cardiac death, ischaemic stroke and transient ischaemic attack.
3. The use according to claim 1, wherein the disease is acute coronary syndromes.
4. The use according to claim 1, wherein the disease is myocardial infarction.
5. The use according to any one of claims 1 to 4, wherein the P2Y₁₂ receptor antagonist

15 is to be administered prior to hospitalization.
6. The use according to claim 5, wherein the P2Y₁₂ receptor antagonist is to be administered by patient self-administration.
7. Use of a P2Y₁₂ receptor antagonist, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the emergency treatment of suspected acute coronary syndromes by patient self-administration prior to hospitalization; wherein

20 the P2Y₁₂ receptor antagonist is 4-((*R*)-2-[[6-((*S*)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino]-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester; and wherein the P2Y₁₂ receptor antagonist is to be administered to a patient by subcutaneous administration.
8. The use according to any one of claims 1 to 7, wherein the amount of 4-((*R*)-2-[[6-((*S*)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino]-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is to be administered is comprised between 1 mg and 75 mg per administration.
9. The use according to any one of claims 1 to 8, wherein the P2Y₁₂ receptor antagonist

25 is to be administered in a bolus injection.
10. The use according to any one of claims 1 to 9, wherein an inhibition of platelet aggregation of at least 75% is reached within 30 min after onset of administration of the P2Y₁₂ receptor antagonist in at least 80% of the patients.
11. Use of 4-((*R*)-2-[[6-((*S*)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino]-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the

35

treatment of a disease, wherein the disease is selected from acute coronary syndromes, myocardial infarction, peripheral ischaemia, amaurosis, sudden cardiac death, ischaemic stroke and transient ischaemic attack, and wherein the medicament is to be administered to a patient by subcutaneous administration.

- 5 12. Use of the P2Y₁₂ receptor antagonist 4-((*R*)-2-[[6-((*S*)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino]-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the emergency treatment of suspected acute coronary syndromes by patient self-administration prior to hospitalization; wherein
- 10 the P2Y₁₂ receptor antagonist is to be administered to a patient by subcutaneous administration.